Assessment of hearing in very young children receiving carboplatin for retinoblastoma

Cas Smits; Suzanne J. Swen; S. Theo Goverts; Annette C. Moll; Saskia M. Imhof; Antoinette Y.N. Schouten-Van Meeteren

doi:10.1016/j.ejca.2005.11.004

Assessment of hearing in very young children receiving carboplatin for retinoblastoma

Cas Smits^*, Suzanne J. Swen, S. Theo Goverts, Annette C. Moll, Saskia M. Imhof, Antoinette Y.N. Schouten-Van Meeteren

^*Corresponding author for this work

Infection & Immunity

Research output: Contribution to journal › Article › Academic › peer-review

28 Citations (Scopus)

Abstract

Children with retinoblastoma have increasingly been treated with carboplatin in the past decade. Ototoxicity is a known, possible, side-effect of carboplatin. Since retinoblastoma patients are very young and frequently have impaired vision, the evaluation of hearing loss is very important. The hearing status of 25 children with retinoblastoma treated with carboplatin (median cumulative dose 2240 mg/m²) was evaluated in detail. Median age at first carboplatin administration was 7 months. The evaluation of hearing loss was performed by an age-appropriate measurement protocol consisting of tympanometry, otoacoustic emission measurements, auditory brainstem responses and (high-frequency) visual reinforcement audiometry (VRA) or play-audiometry. The median follow-up time after last carboplatin dose was 25 months (range 1-94 months). In none of the children was hearing loss detected after carboplatin administration. A measurement protocol that includes tympanometry, distortion product otoacoustic emission measurements and high-frequency VRA is recommended for young children receiving carboplatin or other ototoxic drugs.

Original language	English
Pages (from-to)	492-500
Number of pages	9
Journal	European Journal of Cancer
Volume	42
Issue number	4
DOIs	https://doi.org/10.1016/j.ejca.2005.11.004
Publication status	Published - 1 Mar 2006

Keywords

Carboplatin
Children
Hearing
Ototoxicity
Retinoblastoma
Thermochemotherapy

Access to Document

10.1016/j.ejca.2005.11.004

Cite this

@article{622eacae326c4cac8ad689ed258f7788,

title = "Assessment of hearing in very young children receiving carboplatin for retinoblastoma",

abstract = "Children with retinoblastoma have increasingly been treated with carboplatin in the past decade. Ototoxicity is a known, possible, side-effect of carboplatin. Since retinoblastoma patients are very young and frequently have impaired vision, the evaluation of hearing loss is very important. The hearing status of 25 children with retinoblastoma treated with carboplatin (median cumulative dose 2240 mg/m2) was evaluated in detail. Median age at first carboplatin administration was 7 months. The evaluation of hearing loss was performed by an age-appropriate measurement protocol consisting of tympanometry, otoacoustic emission measurements, auditory brainstem responses and (high-frequency) visual reinforcement audiometry (VRA) or play-audiometry. The median follow-up time after last carboplatin dose was 25 months (range 1-94 months). In none of the children was hearing loss detected after carboplatin administration. A measurement protocol that includes tympanometry, distortion product otoacoustic emission measurements and high-frequency VRA is recommended for young children receiving carboplatin or other ototoxic drugs.",

keywords = "Carboplatin, Children, Hearing, Ototoxicity, Retinoblastoma, Thermochemotherapy",

author = "Cas Smits and Swen, {Suzanne J.} and {Theo Goverts}, S. and Moll, {Annette C.} and Imhof, {Saskia M.} and {Schouten-Van Meeteren}, {Antoinette Y.N.}",

year = "2006",

month = mar,

day = "1",

doi = "10.1016/j.ejca.2005.11.004",

language = "English",

volume = "42",

pages = "492--500",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Assessment of hearing in very young children receiving carboplatin for retinoblastoma

AU - Smits, Cas

AU - Swen, Suzanne J.

AU - Theo Goverts, S.

AU - Moll, Annette C.

AU - Imhof, Saskia M.

AU - Schouten-Van Meeteren, Antoinette Y.N.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Children with retinoblastoma have increasingly been treated with carboplatin in the past decade. Ototoxicity is a known, possible, side-effect of carboplatin. Since retinoblastoma patients are very young and frequently have impaired vision, the evaluation of hearing loss is very important. The hearing status of 25 children with retinoblastoma treated with carboplatin (median cumulative dose 2240 mg/m2) was evaluated in detail. Median age at first carboplatin administration was 7 months. The evaluation of hearing loss was performed by an age-appropriate measurement protocol consisting of tympanometry, otoacoustic emission measurements, auditory brainstem responses and (high-frequency) visual reinforcement audiometry (VRA) or play-audiometry. The median follow-up time after last carboplatin dose was 25 months (range 1-94 months). In none of the children was hearing loss detected after carboplatin administration. A measurement protocol that includes tympanometry, distortion product otoacoustic emission measurements and high-frequency VRA is recommended for young children receiving carboplatin or other ototoxic drugs.

AB - Children with retinoblastoma have increasingly been treated with carboplatin in the past decade. Ototoxicity is a known, possible, side-effect of carboplatin. Since retinoblastoma patients are very young and frequently have impaired vision, the evaluation of hearing loss is very important. The hearing status of 25 children with retinoblastoma treated with carboplatin (median cumulative dose 2240 mg/m2) was evaluated in detail. Median age at first carboplatin administration was 7 months. The evaluation of hearing loss was performed by an age-appropriate measurement protocol consisting of tympanometry, otoacoustic emission measurements, auditory brainstem responses and (high-frequency) visual reinforcement audiometry (VRA) or play-audiometry. The median follow-up time after last carboplatin dose was 25 months (range 1-94 months). In none of the children was hearing loss detected after carboplatin administration. A measurement protocol that includes tympanometry, distortion product otoacoustic emission measurements and high-frequency VRA is recommended for young children receiving carboplatin or other ototoxic drugs.

KW - Carboplatin

KW - Children

KW - Hearing

KW - Ototoxicity

KW - Retinoblastoma

KW - Thermochemotherapy

UR - http://www.scopus.com/inward/record.url?scp=32444432615&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2005.11.004

DO - 10.1016/j.ejca.2005.11.004

M3 - Article

C2 - 16376542

AN - SCOPUS:32444432615

SN - 0959-8049

VL - 42

SP - 492

EP - 500

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 4

ER -

Assessment of hearing in very young children receiving carboplatin for retinoblastoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this